Go Pro
→ Introducing The Early Bird Stock of the Day (From The Early Bird) (Ad)tc pixel Free CRSP Stock Alerts

CRISPR Therapeutics (CRSP) Earnings Date, Estimates & Call Transcripts

CRISPR Therapeutics logo
$57.72 -1.65 (-2.78%)
As of 08/28/2026 04:00 PM Eastern
Compare

CRISPR Therapeutics Earnings Summary

CRISPR Therapeutics issued Q2 2026 earnings on August 3, 2026, reporting an EPS of -$0.94, which beat analysts' consensus estimates of -$1.19 by $0.25. Quarterly revenue rose 1033.3% year-over-year to $10.18 million, above the consensus estimate of $7.45 million. With a trailing EPS of -$4.76, CRISPR Therapeutics' earnings are expected to grow next year, from ($4.47) to ($3.61) per share.

Upcoming Q3
Earnings Date
Nov. 9After Market ClosesEstimated
Consensus EPS
(Aug. 3)
-$1.19
Actual EPS
(Aug. 3)
-$0.94 Beat By $0.25
Actual Revenue
(Aug. 3)
$10.18M

Q2 2026 Earnings Resources

CRSP Upcoming Earnings

CRISPR Therapeutics' next earnings date is estimated for Monday, November 9, 2026, based on past reporting schedules.

Powered by Quartr
Get CRISPR Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

CRSP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CRSP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CRISPR Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20264-$1.38-$0.90-$1.10
Q2 20265-$1.28-$0.81-$1.05
Q3 20265-$1.40-$0.82-$1.21
Q4 20265-$1.87-$0.82-$1.29
FY 2026 19 -$5.93 -$3.35 -$4.64
Q1 20272-$1.27-$1.27-$1.27
Q2 20272-$1.19-$1.16-$1.18
Q3 20271-$1.29-$1.29-$1.29
Q4 20271-$1.24-$1.24-$1.24

CRISPR Therapeutics Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/9/2026
(Estimated)		--------
8/3/2026Q2 2026-$1.19-$0.94+$0.25-$0.94$7.45M$10.18M
6/30/2026Q2 2026--$0.94--$0.94-$10.18M
5/4/2026Q1 2026-$1.2185-$1.28 -$0.0615-$1.28$6.06M$1.46M
3/31/2026Q1 2026--$1.28--$1.28-$1.46M
2/13/2026Q4 2025-$1.15-$1.37 -$0.22-$1.37$4.72M$0.86M
11/10/2025Q3 2025-$1.32-$1.17+$0.15-$1.17$8.74M$0.89M
8/4/2025Q2 2025-$1.47-$1.29+$0.18-$2.40$6.44M$0.89M
5/6/2025Q1 2025-$1.27-$1.58 -$0.31-$1.58--
2/11/2025Q4 2024-$1.15-$0.44+$0.71-$0.44--
11/5/2024Q3 2024-$1.42-$1.01+$0.41-$1.01$6.65M$0.60M
A $382 trillion migration and the position no one is talking about (Ad)

Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.tc pixel

Click here to see the full research and the position name

CRISPR Therapeutics Earnings - Frequently Asked Questions

CRISPR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 9th, 2026 based off last year's report dates. Learn more on CRSP's earnings history.

In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) reported ($0.94) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.19) by $0.25. Learn more on analysts' earnings estimate vs. CRSP's actual earnings.

CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $3.51 million.

CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of -$581.60 million. CRSP has generated -$4.76 earnings per share over the last four quarters.

CRISPR Therapeutics' earnings are expected to grow from ($4.47) per share to ($3.61) per share in the next year.

Related Companies
Earnings Tools

Earnings data for NASDAQ:CRSP is sourced from Fiscal.ai, with the most recent quarter reported on 8/3/2026. New results are added as companies report their earnings.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel